Steris Plc (STE) Stock Price & Analysis
Steris Plc (STE) rose 1.63% to USD 214.07 as of July 25, 2026 at 01:43 UTC, according to Nexqual real-time market data.
STE last closed at USD 210.64; the session ranged USD 211.95–215.9 on volume of 329,076 shares. Market capitalization is $20.86B, with a 52-week range of USD 195.14–269.44 (NYQ). Source: Nexqual, July 25, 2026 at 01:43 UTC.
Key Statistics (as of July 25, 2026 at 01:43 UTC)
| Price | USD 214.07 |
|---|---|
| Change | ▲ 1.63% (up) |
| Previous Close | USD 210.64 |
| Open | USD 212.85 |
| Day Range | USD 211.95 – 215.9 |
| 52-Week Range | USD 195.14 – 269.44 |
| Volume | 329,076 shares |
| Market Cap | $20.86B |
| Exchange | NYQ |
Technical Analysis (STE)
Nexqual's technical model rates STE "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 01:43 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 50.75 (neutral) |
| vs SMA50 | Above (USD 211.82) |
| MACD | 0.51 (positive) |
Analyst Ratings (STE)
Wall Street analysts rate STE "Buy" based on 7 analysts, with a mean price target of USD 252.57 (range USD 225–280), per Nexqual as of July 25, 2026 at 01:43 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 252.57 |
| High Target | USD 280 |
| Low Target | USD 225 |
| Buy / Hold / Sell | 6 / 2 / 0 |
Earnings (STE)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 2.49 |
| Revenue Estimate | $1.50B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.83 vs est 2.85 ▼ miss |
| 2025-12-31 | USD 2.53 vs est 2.53 ▼ miss |
| 2025-09-30 | USD 2.47 vs est 2.35 ▲ beat |
| 2025-06-30 | USD 2.34 vs est 2.26 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:43 UTC.
Financials & Fundamentals (STE)
| Total Revenue | $5.94B |
|---|---|
| Revenue Growth (YoY) | +7.30% |
| Gross Margin | +44.24% |
| Operating Margin | +20.04% |
| Profit Margin | +13.18% |
| ROE | +11.37% |
| Debt / Equity | 29 |
| Current Ratio | 2.09 |
| Total Cash | $439.60M |
| Total Debt | $2.09B |
| Free Cash Flow | $837.29M |
Source: Nexqual, July 25, 2026 at 01:43 UTC.
Financial Health Score (STE)
Nexqual rates Steris Plc's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:43 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 44%, operating 20% |
| Balance Sheet | Strong — $440M cash vs $2.09B debt |
| Cash Flow | Solid — FCF $837M, 14% margin |
| Efficiency | Mixed — ROE 11%, ROA 6.7% |
Ownership (STE)
| Insider Ownership | +0.31% |
|---|---|
| Institutional Ownership | +100.68% |
| Shares Outstanding | 97.46M |
| Float | 97.18M |
| Short % of Float | +2.41% |
Source: Nexqual, July 25, 2026 at 01:43 UTC.
Leadership (STE)
Steris Plc is led by Daniel A. Carestio (age 52), President, CEO & Director, per Nexqual as of July 25, 2026 at 01:43 UTC.
| President, CEO & Director | Daniel A. Carestio (age 52) |
|---|---|
| Senior VP, CFO & Chief Accounting Officer | Karen L. Burton (age 57) |
| Senior VP & President of Healthcare | Cary L. Majors (age 50) |
| Vice President of Investor Relations & Corporate Communications | Julie Winter |
Major Backers & Investors (STE)
Notable institutional backers of Steris Plc include Morgan Stanley, Massachusetts Financial Services Co., Wellington Management, according to Nexqual as of July 25, 2026 at 01:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 4.51% |
| Massachusetts Financial Services Co. | 4.11% |
| Wellington Management | 2.95% |
| Orbis Allan Gray Ltd | 2.66% |
| Generation Investment Management LLP | 2.37% |
| Fidelity | 1.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 20.65% |
| BlackRock | 10.59% |
| State Street | 6.34% |
| Geode Capital | 2.65% |
Source: Nexqual, July 25, 2026 at 01:43 UTC.
From Steris Plc's Latest SEC 10-K Filing (filed 2026-05-29)
Key Strengths & Strategy (as disclosed to the SEC)
- STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally.
- It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences.
- It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting.
- In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TFX | Teleflex Incorporated | USD 132.1 | ▼ 2% |
| COO | The Cooper Companies, Inc. | USD 70.31 | ▼ 0.27% |
| MTD | Mettler-Toledo International, I | USD 1,327.18 | ▲ 3.21% |
| WST | West Pharmaceutical Services, I | USD 328.2 | ▼ 8.43% |
| RMD | ResMed Inc. | USD 195.27 | ▲ 1.22% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:43 UTC. This page is informational and not investment advice.